89 results about "Benzodiazepine" patented technology

The disclosure provides methods for treating a patient in need thereof comprising co-administering to the patient a therapeutically-effective dose of psilocybin and one or more benzodiazepines. The present disclosure also provides methods to reduce the SSRI washout period in patients prior to administration of psilocybin therapy.

The invention relates to pharmaceutical compositions comprising one or more benzodiazepine drugs for nasal administration, methods for producing and for using such compositions.

The invention relates to pharmaceutical compositions comprising one or more benzodiazepine drugs for nasal administration, methods for producing and for using such compositions.

The invention relates to pharmaceutical compositions comprising one or more benzodiazepine drugs for nasal administration, methods for producing and for using such compositions.

The invention relates to pharmaceutical compositions comprising one or more benzodiazepine drugs for nasal administration, methods for producing and for using such compositions.

This invention relates to benzodiazepine derivatives, compositions comprising therapeutically effective amounts of those derivatives and methods of using those derivatives or compositions in treating cognitive impairment associated with CNS disorders. It also relates to the use of an α5-containing GABAA receptor agonist (e.g., an α5-containing GABAA receptor positive allosteric modulator) in treating cognitive impairment associated with CNS disorders in a subject in need or at risk thereof, including age-related cognitive impairment, Mild Cognitive Impairment (MCI), amnestic MCI, Age-Associated Memory Impairment, Age Related Cognitive Decline, dementia, Alzheimer's Disease (AD), prodromal AD, PTSD, schizophrenia, bipolar disorder, ALS, cancer-therapy-related cognitive impairment, mental retardation, Parkinson's disease, autism spectrum disorders, fragile X disorder, Rett syndrome, compulsive behavior, and substance addiction. It also relates to the use of an α5-containing GABAA receptor agonist (e.g., an α5-containing GABAA receptor positive allosteric modulator) in treating brain cancers (including brain tumors, e.g., medulloblastomas), and cognitive impairment associated therewith.

Disclosed in the present invention are a benzodiazepine compound, a pharmaceutical composition and the use thereof. Specifically provided is a compound represented by formula I, or a stereoisomer thereof, a deuterated compound thereof, or a pharmaceutically acceptable salt thereof. The compound provided in the present invention has one or more of the following advantageous effects: (1) the compound of the present invention exhibits good intravenous sedative and anesthetic effects; (2) the compound of the present invention exhibits low drug accumulation and a good tolerance; and (3) the compound of the present invention achieves an anesthetic effect with faster recovery.

Disclosed is a preparation method for a 1,5-dihydro-2,4-benzodiazepine-3-one derivative. According to the preparation method, required raw materials are cheap and easily available; the use of a flammable and explosive reagent namely borane, a difficult-to-handle and highly-toxic reagent namely triphosgene, and a precious metal namely palladium is avoided; the operation is simple and convenient, production costs are reduced; and the preparation method is more suitable for industrial preparation and use, and has higher yield than that of the prior art. Additionally, further disclosed are an intermediate as shown in formula III or a salt thereof for preparing the derivative, and a preparation method for the intermediate or salt.

The invention relates to pharmaceutical compositions comprising one or more benzodiazepine drugs for nasal administration, methods for producing and for using such compositions.

Methods and compositions are provided for treating individuals exhibiting opioid withdrawal symptoms with opioid, benzodiazepine and other drugs of abuse by administering an opioid receptor antagonist agent together with a respiratory stimulant to reverse the effects of opioid withdrawal symptoms, including respiratory depression, sedation, and hypotension. Methods and compositions are also provided for treating stimulant overdose with a benzodiazepine and beta-adrenergic blocking agent. Methods and compositions are also provided for treating concurrent stimulant and opioid overdose comprising administering to a patient in need thereof a benzodiazepine and an opioid antagonist. Methods and compositions are also provided for treating individuals exhibiting opioid withdrawal symptoms or prophy tactically treating individuals for opioid withdrawal symptoms from opioid, benzodiazepine and other drugs of abuse by administering an opioid receptor antagonist agent together with a respiratory stimulant to reverse the effects of withdrawal, including respiratory depression, sedation, and hypotension.

The present invention relates to antibody conjugates which are particularly suitable for targeting cells expressing PTK7, in particular tumor cells. An antibody conjugate according to the present invention has structure (1): AB-[(L6) b-{Z-L-D} x] y (1) wherein AB is an antibody capable of targeting a tumor expressing PTK7; l is a joint connecting Z to D; z is a linking group; l6 is-GlcNAc (Fuc) w-(G) j-S-(L7) w '-wherein G is a monosaccharide, j is an integer in the range of 0 to 10, S is a sugar or a sugar derivative, GlcNAc is N-acetylglucosamine, and Fuc is fucose, w is 0 or 1, w' is 0, 1 or 2, and L7 is-N (H) C (O) CH2-,-N (H) C (O) CF2-or-CH2-; d is selected from the group consisting of an anthracycline, a camptothecin, a tubulysin, an endiyne, an amanitine, a duocarmycin, a maytansinoid, an aurestatin, eribulin, a BCL-XL inhibitor, a miscanthus semiaquilaria, a KSP inhibitor, a TLR agonist, an indolo-benzodiazepine dimer or a pyrrolo-benzodiazepine dimer (PBD), and an analog or prodrug thereof; b is 0 or 1; x is 1 or 2; and y is 1, 2, 3 or 4. The invention further relates to a method for preparing said antibody conjugate of structure (1) and to the use of said antibody conjugate of structure (1).

The invention relates to the technical field of traditional Chinese medicine compositions, in particular to a traditional Chinese medicine composition for treating insomnia and a preparation method thereof. The traditional Chinese medicine composition is prepared from the following raw material components in parts by weight: 7 to 11 parts of radix bupleuri, 7 to 11 parts of radix curcumae, 10 to 15 parts of radix codonopsis, 8 to 12 parts of rhizoma atractylodis macrocephalae, 4 to 8 parts of rhizoma pinelliae, 4 to 8 parts of caulis bambusae in taeniam, 12 to 18 parts of bulbus lilii, 8 to 13 parts of radix ophiopogonis, 10 to 14 parts of radix salviae miltiorrhizae, 12 to 18 parts of fossil fragments, 13 to 17 parts of nacre mother of pearl and 4 to 8 parts of radix glycyrrhizae preparata. The traditional Chinese medicine composition takes liver soothing, spleen strengthening, phlegm reducing and nerve calming as the core, has the effects of nourishing yin and activating blood, and regulates the function of a human body from multiple aspects through the synergistic effect of multiple medicinal materials, so that the effect of improving the sleep quality is achieved, and the adverse reaction rate is lower than that of a Western medicine benzodiazepine medicine.

The invention system is a wearable device that detects an impending or onset of cardio-respiratory arrest and remediates the condition by injecting an appropriate reversal drug depending upon the drug that triggered the arrest. It can detect and remediate arrests caused by drugs such as opioids, benzodiazepine or alcohol. Using self-test and other checks, it ensures that the system is operationally ready and that no near-expiration or expired drug is administered.

The present application relates to the technical field of copper-clad plate preparation, and particularly relates to a halogen-free flame-retardant BT resin-based copper-clad plate and a preparation method thereof. The present application adds 3,4-dihydroxybenzaldehyde, triethylamine, 7-chloro-1,3-dihydro-5-phenyl-2H-1,4-benzodiazepine-2-thione and ethyl acetate to prepare an antibacterial monomer. Then, the Zn-MOF material, the antibacterial monomer and 9,10-dihydro-9-oxa-10-phosphaphenanthrene-10-oxide are used to prepare a flame retardant. Finally, the cyanate ester resin, the bismaleimide resin, the epoxy resin, the flame retardant, the solvent, the filler and the curing agent are added to prepare a resin glue solution. The glass fiber cloth is immersed in the resin glue solution, and then high-temperature curing, copper foil lamination and laminated molding are performed to prepare a finished product. The finished product prepared by the present application has good flame retardance and antibacterial property, and therefore has a wide application prospect in the technical field of copper-clad plate preparation.

Compositions for intranasal delivery of benzodiazepines, such as diazepam, midazolam, and lorazepam and methods for their use to treat and prevent seizures in pediatric subjects aged 2-5, inclusive. Compositions for rapid therapeutic onset with a decreased incidence and / or severity of adverse effects after administration and methods of improving patient compliance with a prescribed treatment regimen.

The invention discloses application of a selfheal compound in preparation of a medicine for adjusting an insomnia sleep structure. The selfheal compound comprises selfheal, rhizoma acori graminei, herba cepbalanoplosis segeti, semen boitae and caulis bambusae in taeniam. The selfheal compound can remarkably improve the sleep structure, and compared with a traditional benzodiazepine medicine (such as diazepam), the selfheal compound not only effectively recovers the physiological proportion of non-rapid eye movement sleep and rapid eye movement sleep, but also can reduce sleep fragmentation and rebuild sleep continuity.

This invention discloses an acylhydrazone-linked covalent organic framework material, its preparation method, and its application, belonging to the field of covalent organic framework material synthesis technology. The preparation method of the acylhydrazone-linked covalent organic framework material is as follows: benzo[1,2-b:3,4-b':5,6-b”]trithiophene-2,5,8-tricarboxaldehyde, benzodiazepine, o-dichlorobenzene, and n-butanol are mixed to obtain suspension A; trifluoroacetic acid is added to suspension A and mixed to obtain mixture A; mixture A is sequentially subjected to freeze degassing and heating treatment, followed by extraction to obtain the final product. This invention uses benzo[1,2-b:3,4-b':5,6-b”]trithiophene-2,5,8-tricarboxaldehyde and benzodiazepine with a specific structure as main raw materials, and by adjusting the concentration, type, and amount of catalyst, an acylhydrazone-linked covalent organic framework material with higher crystallinity and stability is prepared.

This invention belongs to the fields of medicinal chemistry and pharmaceutical technology, and relates to 1,4-benzodiazepines and their use in the preparation of antitumor drugs, specifically the use of 1,4-benzodiazepines in the preparation of annexin A3 (ANXA3) degrading agents and in the preparation of drugs for treating cancer. In particular, it discloses the use of 1,4-benzodiazepines, or pharmaceutically acceptable salts thereof, or stereoisomers thereof, or compositions of drugs with these as active ingredients, in the preparation of drugs for the prevention and treatment of tumors. These compounds can bind to the ANXA3 protein, induce ANXA3 protein degradation, inhibit the proliferation, cloning, migration, and invasion of tumor cells, and exert antitumor therapeutic effects in vivo. They can be used to treat solid tumors and hematological malignancies, including breast cancer, cervical cancer, ovarian cancer, colorectal cancer, gastric cancer, pancreatic cancer, lung cancer, esophageal cancer, liver cancer, leukemia, and melanoma.

A conjugate obtained by binding a benzodiazepine to an antibody or an antigen-binding fragment thereof having immunological reactivity with MCEMP1 protein, the conjugate being an antibody-drug complex (ADC) having a strong anti-tumor effect and being useful for the treatment and / or prevention of cancer, particularly cancer expressing MCEMP1 protein on the cell surface.

The present disclosure relates to a pyrrolo benzodiazepine derivative and a conjugate, preparation method and use thereof. In particular, the present disclosure relates to a compound of formula (DL) and a antibody-drug conjugate thereof, a pharmaceutical composition containing same, and a use thereof in the preparation of a medicament for the treatment of cancer. The definitions of groups in the general formula (DL) are as defined in the description.

The present invention relates to processes for preparing Compound (I) or a pharmaceutically acceptable salt or solvate thereof. In particular, such processes comprise cyclodehydration of a 1,2-diacylhydrazine intermediate to form the corresponding 1,3,4-oxadiazole where the cyclodehydration agent may be N,N-dimethylsulfamoyl chloride, methyl N-(triethyIammoniumsulfonyl)carbamate, phosphorus trichloride, or phosphorus pentachloride, resulting in increased product yield and purity compared to known methods. Compound (I) and pharmaceutical compositions thereof are useful as Respiratory Syncytial Virus (RSV) inhibitors.

The present invention discloses compounds of Formula (I), or pharmaceutically acceptable salts, esters, or prodrugs thereof:which inhibit Respiratory Syncytial Virus (RSV). The present invention further relates to pharmaceutical compositions comprising the aforementioned compounds for administration to a subject suffering from RSV infection. The invention also relates to methods of treating an RSV infection in a subject by administering a pharmaceutical composition comprising the compounds of the present invention.

The invention discloses a deuterated compound of benzodiazepine and application thereof, the deuterated compound of benzodiazepine has the following general formula: in the formula, R1 and R2 are independently selected from ethyl or deuterated ethyl, R3 to R18 are independently selected from H group or deuterated group, and R1 to R18 at least contain one deuterated group. The deuterated compound of benzodiazepine or the pharmaceutically acceptable salt, hydrate or solvent compound thereof provided by the invention has a muscarinic M2 receptor antagonism effect, and compared with a known selective M2 receptor inhibitor, the compound provided by the invention has better inhibitory activity and pharmacodynamic performance, has little influence on the activity of an M3 receptor, and can be used for preparing a novel compound of benzodiazepine or a pharmaceutically acceptable salt, hydrate or solvent compound of benzodiazepine. The side effect of pupil dilation (mydriasis) is avoided, and the composition has a good development prospect in clinical application of treating myopia, preventing myopia and / or inhibiting myopia development.

The present invention provides a pharmaceutical composition containing a benzodiazepine drug. [Solution] A drug solution for intranasal administration is provided, comprising: (a) a benzodiazepine drug; (b) one or more natural or synthetic tocopherols or tocotrienols, or any combination thereof, in an amount of about 30% to about 95% (w / w); (c) one or more alcohols or glycols, or any combination thereof, in an amount of about 10% to about 70% (w / w); and (d) an alkyl glycoside.

This invention discloses an AI-designed benzodiazepine derivative, a pharmaceutical composition, and its uses. The benzodiazepine derivative has the structure of Formula I: wherein R1 is any one of H, deuterium, halogen, or C1-C3 alkoxy group; A is a nitrogen-containing heterocyclic group; n is 0 or 1; and R2 and R3 are hydrogen, C1-C6 alkyl group, or C4-C6 alkyl group. 20 Any of the polycyclic cycloalkyl groups; or, R2 and R3 can form a C4-C4 group together with the N they are attached to. 20 The polycyclic heterocyclic group structure. The benzodiazepine derivative of this invention, as the active ingredient in drugs for preventing and / or inhibiting myopia progression, can significantly improve selectivity for M2 receptors and significantly reduce inhibitory effects on M3 receptors, with an M3 / M2 IC50 ratio. 50 The ratio increases significantly, enabling effective treatment of myopia without affecting pupil size, and helps improve the targeted nature of treatment and patient comfort.